The third edition of the book Essentials of Pharmacoeconomics: Health Economics and Outcomes Research is now available.
The publisher shares, “This updated edition provides the critical foundations of knowledge for measuring costs and health-related quality-of-life (HRQoL) and evaluating the four types of studies (CMA, CEA, CUA, and CBA); it also explains Markov and Budget Impact Analysis modeling and discusses the advantages and disadvantages of using retrospective databases and real-world data (RWD) [It] is designed to ensure preparedness to improve clinical and humanistic outcomes based on available resources.”
Jo Mauskopf, PhD, and Stephanie Earnshaw, PhD, of RTI Health Solutions, contributed a new chapter on budget-impact analysis to the book. Chapter 12 explains the need for a budget-impact analysis and how it differs from cost-effectiveness analysis. Readers will learn about implementing analyses and critiquing a budget-impact analysis composite article.
Earnshaw shared, “Being asked to provide content for academia about what a high-quality budget-impact analysis encompasses demonstrates that there is a recognition that it is important to train individuals to construct these analyses appropriately for decision makers.”
Essentials of Pharmacoeconomics: Health Economics and Outcomes Research can be found online and in bookstores.